Cargando…

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients

PURPOSE: This research was intended to explore the effects of new-generation basal insulin (degludec U100 And glargine U300) versus long-acting basal insulin (glargine U100, detemir) on the incidence of diabetic ketoacidosis episodes and diabetes treatment measures. PATIENTS AND METHODS: This is a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsofiani, Wafa A, Alessa, Bandar H, Alsabaan, Fahad, Althemery, Abdullah U, Ghith, Aliah M, Alfaifi, Abdullah A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906698/ https://www.ncbi.nlm.nih.gov/pubmed/35280501 http://dx.doi.org/10.2147/DMSO.S351155

Ejemplares similares

Diabetic Ketoacidosis Updates: Titratable Insulin Infusions and Long-Acting Insulin Early
por: Kinney, Justin, et al.
Publicado: (2021)

An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
por: Gilor, Chen, et al.
Publicado: (2021)

Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs
por: Hulsebosch, Sean E., et al.
Publicado: (2022)

Erratum for “Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs”
Publicado: (2023)

Erratum for “An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats”
Publicado: (2023)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Long-acting insulin allergy in a diabetic child
por: Mastrorilli, Carla, et al.
Publicado: (2017)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
por: Birkeland, Kåre I., et al.
Publicado: (2011)

Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment
por: Schroeder, Emily B., et al.
Publicado: (2021)

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
por: Raslova, Katarina
Publicado: (2010)

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
por: Hui, Elaine, et al.
Publicado: (2013)

Long-Acting Insulin Analogs and the Risk of Diabetic Ketoacidosis in Children and Adolescents With Type 1 Diabetes: A prospective study of 10,682 patients from 271 institutions
por: Karges, Beate, et al.
Publicado: (2010)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs
por: Hegab, Ahmed M.
Publicado: (2022)

Serious diabetic ketoacidosis induced by insulin allergy and anti‐insulin antibody in an individual with type 2 diabetes mellitus
por: Takahashi, Kaio, et al.
Publicado: (2022)

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study
por: Gordon, J, et al.
Publicado: (2010)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
por: Davies, M J, et al.
Publicado: (2009)

Isoproterenol Induced Insulin Resistance Leading to Diabetic Ketoacidosis in Type 1 Diabetes Mellitus
por: Hoff, Ryan, et al.
Publicado: (2018)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
por: Edwards, Krystal L., et al.
Publicado: (2006)

Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
por: Wong, Eva Y., et al.
Publicado: (2021)

Safety and Efficacy of Long-Acting Insulins Degludec and Glargine Among Asian Patients With Type 2 Diabetes Mellitus: A Meta-Analysis
por: Kant, Ravi, et al.
Publicado: (2021)

Management of Diabetic Ketoacidosis in Severe Insulin Resistance
por: Robinson, Cemre, et al.
Publicado: (2016)

Massive Levemir (Long-Acting) Insulin Overdose: Case Report
por: Oduru, Mamatha, et al.
Publicado: (2012)

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil
por: Laranjeira, Fernanda O, et al.
Publicado: (2016)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Glycogenic hepatopathy following attempted suicide by long‐acting insulin overdose in patient with type 1 diabetes
por: Fujisaki, Noritomo, et al.
Publicado: (2020)

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
por: Hansen, Bo F., et al.
Publicado: (2012)

Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
por: Kuroda, Akio, et al.
Publicado: (2013)

Cell Adhesive Character of Phenylboronic Acid-Modified Insulin and Its Potential as Long-Acting Insulin
por: Ohno, Yui, et al.
Publicado: (2019)

Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type 1 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin
por: Moser, Othmar, et al.
Publicado: (2015)

Elasomeran/insulin: Diabetic ketoacidosis, insulin resistance and lack of efficacy: case report
Publicado: (2022)

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2014)

Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: Protocol for a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5fbvb3lo6kphqofr666f94530v